Match tier Confirmed
Presence Current · Arkansas
Last published 2023
Sources OpenAlex · ORCID
Refreshed 2026-08-17

Anshel Bright

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Researcher

Also affiliated: United States Food and Drug Administration (2022–2023)

Graduate Student Researcher

1 h-index 2 pubs 5 cited

  • Biopharmaceutics
  • Nanoparticles
  • Administration, Oral
  • Animals
  • Capsules
  • Female
  • Hydroxyurea
  • Intestinal Mucosa
  • Solubility
  • Cytokines
  • Rats, Sprague-Dawley
  • Rats

Biography and Research Information

OverviewAI-generated summary

Anshel Bright's research investigates the efficacy of nanocrystal formulations for poorly soluble drugs. Their work has focused on evaluating the immune response and risk assessment associated with Zileuton, a BCS-II drug, when formulated as nanocrystals and administered orally. Studies have utilized Sprague Dawley rats to assess mucosal immune profiles, including cytokine levels, and to conduct in vivo risk assessments. Bright has co-authored two publications in this area, collaborating with researchers from the National Center for Toxicological Research, including Sangeeta Khare and Kuppan Gokulan.

Metrics

  • h-index: 1
  • Publications: 2
  • Citations: 5

Selected Publications

  • Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats (2023)
    Nanotoxicology 4 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

5 Collaborators 4 Institutions 1 Country

Top Collaborators

View profile →
View profile →

Similar Researchers

Based on overlapping research topics